Cara Therapeutics
Biotechnology, 107 Elm St, Stamford, Connecticut, 06902, United States, 51-200 Employees
Phone Number: 20********
Who is CARA THERAPEUTICS
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Companys KORSUVA (difelike...
Read More
-
Headquarters: 107 Elm St, Stamford, Connecticut, 06902, United States
-
Date Founded: 2004
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from CARA THERAPEUTICS
Cara Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Cara Therapeutics
Answer: Cara Therapeutics's headquarters are located at 107 Elm St, Stamford, Connecticut, 06902, United States
Answer: Cara Therapeutics's phone number is 20********
Answer: Cara Therapeutics's official website is https://caratherapeutics.com
Answer: Cara Therapeutics's revenue is $25 Million to $50 Million
Answer: Cara Therapeutics's SIC: 2834
Answer: Cara Therapeutics's NAICS: 541715
Answer: Cara Therapeutics has 51-200 employees
Answer: Cara Therapeutics is in Biotechnology
Answer: Cara Therapeutics contact info: Phone number: 20******** Website: https://caratherapeutics.com
Answer: Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Companys KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month